This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.
The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Males and females with chronic plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at screening and first admission to the clinical site
Exclusion Criteria:
Pregnant or nursing (lactating) History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection Have major surgery within 8 weeks prior to first admission to the clinical site or during the study Have a history of lymphoma, leukemia, or any malignancy Require treatment with the cocktail drugs within 14 days prior to the first administration of the drug cocktail through the end of Week 12 assessments Have participated in any other study with mirikizumab
